{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:00Z","timestamp":1792818960239,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1053\/j.akdh.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T20:22:24Z","timestamp":1732134144000},"page":"485-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rapidly Progressive Glomerulonephritis"],"prefix":"10.1053","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2154-0893","authenticated-orcid":false,"given":"Abbal","family":"Koirala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva D.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6951-7591","authenticated-orcid":false,"given":"Koyal","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-5542","authenticated-orcid":false,"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.akdh.2024.08.006_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0272-6386(88)80079-9","article-title":"Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy","volume":"11","author":"Couser","year":"1988","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2024.08.006_bib2","first-page":"479","article-title":"Update on crescentic glomerulonephritis","volume":"36","author":"H\u00e9nique","year":"2014","journal-title":"Semin Immunopathol, Springer Berlin Heidelberg"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib3","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","article-title":"Rapidly progressive crescentic glomerulonephritis","volume":"63","author":"Jennette","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.md.0000224709.70133.f7","article-title":"Predictors of survival in systemic lupus erythematosus","volume":"85","author":"Kasitanon","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.38239","article-title":"The incidence and prevalence of systemic lupus erythematosus, 2002\u20132004: the Georgia Lupus Registry","volume":"66","author":"Lim","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program","volume":"66","author":"Somers","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000\u20132004","volume":"65","author":"Feldman","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0002-9343(96)00074-5","article-title":"End-stage renal disease and systemic lupus erythematosus","volume":"101","author":"Mojcik","year":"1996","journal-title":"Am J Med"},{"issue":"9","key":"10.1053\/j.akdh.2024.08.006_bib10","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.24776","article-title":"Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution","volume":"60","author":"Burgos","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1053\/j.akdh.2024.08.006_bib11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.ackd.2019.08.007","article-title":"Lupus nephritis and kidney transplantation: where are we today?","volume":"26","author":"Wong","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"issue":"10","key":"10.1053\/j.akdh.2024.08.006_bib12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.akdh.2024.08.006_bib13","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1053\/j.akdh.2024.08.006_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2024.08.006_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"10289","key":"10.1053\/j.akdh.2024.08.006_bib16","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1053\/j.akdh.2024.08.006_bib17","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus\u2013associated mixed cryoglobulinemia vasculitis: a long-term followup study","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000167955","article-title":"Recurrent essential mixed cryoglobulinemia in renal allografts. Report of two cases and review of the literature","volume":"9","author":"Hiesse","year":"1989","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2024.08.006_bib22","first-page":"1426","article-title":"Renal replacement therapy in cryoglobulinaemic nephritis","volume":"9","author":"Tarantino","year":"1994","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ndt\/12.3.418","article-title":"Survey of the Italian Registry of renal biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of renal Immunopathology","volume":"12","author":"Schena","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.01380217","article-title":"Anti-glomerular basement membrane disease","volume":"12","author":"McAdoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.08.006_bib25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1681\/ASN.V641178","article-title":"Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome","volume":"6","author":"Kalluri","year":"1995","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.ajkd.2004.09.029","article-title":"Recurrent Goodpasture\u2019s disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1\/alpha2 chains of type IV collagen","volume":"45","author":"Borza","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.akdh.2024.08.006_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00277-018-3513-4","article-title":"Anti-glomerular basement membrane disease due to monoclonal IgG Lambda antibodies: a very rare case of monoclonal gammopathy of renal significance","volume":"98","author":"Pe\u00f1a","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/bmme.1996.0064","article-title":"Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis","volume":"59","author":"Litwin","year":"1996","journal-title":"Biochem Mol Med"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ki.2012.375","article-title":"Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease","volume":"83","author":"Tang","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.1994.96","article-title":"COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome","volume":"45","author":"Kalluri","year":"1994","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2024.08.006_bib31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.08.006_bib32","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ekir.2023.03.010","article-title":"Atypical anti-glomerular basement membrane disease","volume":"8","author":"Bharati","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.akdh.2024.08.006_bib33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical Practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.akdh.2024.08.006_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti\u2013glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.08.006_bib35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ekir.2018.12.002","article-title":"Rituximab for anti\u2013glomerular basement membrane disease","volume":"4","author":"Jain","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.akdh.2024.08.006_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2014.92","article-title":"Pathology of IgA nephropathy","volume":"10","author":"Roberts","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/modpathol.2016.77","article-title":"Glomerular IgG deposition predicts renal outcome in patients with IgA nephropathy","volume":"29","author":"Shin","year":"2016","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1053\/j.akdh.2024.08.006_bib38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib39","first-page":"309","article-title":"Recurrent mesangial IgA nephritis following renal transplantation","volume":"9","author":"Odum","year":"1994","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1053\/j.akdh.2024.08.006_bib40","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/00007890-199804270-00008","article-title":"Single-center long-term results of renal transplantation for IgA nephropathy","volume":"65","author":"Bumgardner","year":"1998","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.akdh.2024.08.006_bib41","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/ndt\/gfs472","article-title":"The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival","volume":"28","author":"Moroni","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.akdh.2024.08.006_bib42","first-page":"2054","article-title":"Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy","volume":"10","author":"Roccatello","year":"1995","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib43","first-page":"193","article-title":"Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment","volume":"56","author":"McIntyre","year":"2001","journal-title":"Clin Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib44","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 124","key":"10.1053\/j.akdh.2024.08.006_bib45","first-page":"195","article-title":"Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis","volume":"38","author":"Fenoglio","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"10405","key":"10.1053\/j.akdh.2024.08.006_bib46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1053\/j.akdh.2024.08.006_bib48","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A","article-title":"Antineutrophil cytoplasmic antibodies","volume":"41","author":"Hoffman","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1523-1755.1998.00807.x","article-title":"Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC\/BCR Project for ANCA Assay Standardization","volume":"53","author":"Hagen","year":"1998","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.berh.2004.10.003","article-title":"What do antineutrophil cytoplasmic antibodies (ANCA) tell us?","volume":"19","author":"Savige","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1681\/ASN.V82314","article-title":"ANCA small-vessel vasculitis","volume":"8","author":"Falk","year":"1997","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.08.006_bib52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.08.006_bib53","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ki.2009.218","article-title":"The clinical course of ANCA small-vessel vasculitis on chronic dialysis","volume":"76","author":"Lionaki","year":"2009","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.akdh.2024.08.006_bib54","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/annrheumdis-2018-213452","article-title":"Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System","volume":"77","author":"Wallace","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/BOR.0000000000000006","article-title":"Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"26","author":"Moran","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib56","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical Practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib57","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib58","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.akdh.2024.08.006_bib59","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib61","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"van Leeuwen","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.akdh.2024.08.006_bib62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2023.06.021","article-title":"Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"117","author":"Benavides-Villanueva","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41581-019-0178-8","article-title":"Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis","volume":"16","author":"Satoskar","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.08.006_bib64","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/ki.2014.424","article-title":"Update on endocarditis-associated glomerulonephritis","volume":"87","author":"Boils","year":"2015","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.08.006_bib65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ki.2012.407","article-title":"Bacterial infection-related glomerulonephritis in adults","volume":"83","author":"Nasr","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib66","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2215\/CJN.05070516","article-title":"Staphylococcus infection-associated GN - spectrum of IgA staining and prevalence of ANCA in a single-center cohort","volume":"12","author":"Satoskar","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib67","doi-asserted-by":"crossref","first-page":"c18","DOI":"10.1159\/000324180","article-title":"IgA-dominant postinfectious glomerulonephritis: a new twist on an old disease","volume":"119","author":"Nasr","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib68","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/ndt\/17.7.1204","article-title":"Long-term prognosis of diffuse proliferative glomerulonephritis associated with infection in adults","volume":"17","author":"Moroni","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/md.0b013e318161b0fc","article-title":"Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature","volume":"87","author":"Nasr","year":"2008","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1053\/j.akdh.2024.08.006_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00005792-199503000-00001","article-title":"The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature","volume":"74","author":"Montseny","year":"1995","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1053\/j.akdh.2024.08.006_bib71","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10067-022-06240-w","article-title":"Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature","volume":"41","author":"Van Gool","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1053\/j.akdh.2024.08.006_bib72","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1053\/j.ajkd.2004.01.015","article-title":"Shunt nephritis with positive titers for ANCA specific for proteinase 3","volume":"43","author":"Iwata","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MNH.0b013e3283456731","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis","volume":"20","author":"Jennette","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"7","key":"10.1053\/j.akdh.2024.08.006_bib74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"QJM"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.akdh.2024.08.006_bib77","first-page":"2169","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. Reply","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib78","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can Predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy \u2014 understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.08.006_bib80","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.akdh.2024.08.006_bib81","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib82","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1053\/j.akdh.2024.08.006_bib83","first-page":"4","article-title":"Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange","volume":"75","author":"Krmar","year":"2011","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.08.006_bib84","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T01:20:23Z","timestamp":1733016023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924001460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2949813924001460"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.08.006","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapidly Progressive Glomerulonephritis","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}